{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:08:29Z","timestamp":1791598109789,"version":"4.3.4"},"reference-count":66,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["31860607"],"award-info":[{"award-number":["31860607"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Vancomycin is a first-line drug for the treatment of MRSA infection. However, overuse of vancomycin can cause bacteria to become resistant, forming resistant strains and making infections more difficult to treat. This study aimed to evaluate the efficacy and safety of different antibiotics in the treatment of MRSA infections and to compare them, mainly with vancomycin, to find better vancomycin alternatives. Methods: All studies were obtained from the PubMed and Embase databases from inception to 13 April 2023. The three comprehensive indicators of clinical cure success rate, clinical microbiological success rate, and adverse reactions were evaluated, and the clinical cure success rates of three disease types, complex skin and skin structure infections (cSSSIs), complex skin and soft tissue infections (cSSTIs), and pneumonia, were analyzed in subgroups. All statistical analyses were performed using R and STATA 14.0 software for network meta-analysis. Results: A total of 38 trials with 6281 patients were included, and 13 drug treatments were evaluated. For MRSA infections, the results of network meta-analysis showed that the clinical success rates of linezolid, the combination of vancomycin and rifampin, and the combination of minocycline and rifampin were better than that of vancomycin (RR 1.71; 95%-CI 1.45\u20132.02), (RR 2.46; 95%-CI 1.10\u20135.49) (RR, 2.77; 95%-CI 1.06\u20137.21). The success rate of clinical microbiological treatment with vancomycin was inferior to that with telavancin (RR 0.74; 95%-CI 0.55\u20130.99). Linezolid had a higher rate of adverse reactions than teicoplanin (RR 5.35; 95%-CI 1.10\u201325.98). Subgroup analysis showed that vancomycin had a lower clinical success rate than linezolid in the treatment of MRSA-induced cSSSIs, cSSTIs, and pneumonia (RR 0.59; 95%-CI 0.44\u20130.80) (RR 0.55; 95%-CI 0.35\u20130.89) (RR 0.55; 95%-CI 0.32\u20130.93). Conclusions: This systematic review and NMA provide a new comparison framework for the clinical treatment of MRSA infection. The NMA suggests that linezolid may be the antibiotic of choice for the treatment of MRSA infections, with the ability to improve clinical and microbiological success rates despite its disadvantage in terms of adverse effects. At the same time, the combination of minocycline and rifampicin may be the most effective drug to treat MRSA-induced cSSSIs, tedizolid may be the best drug to treat MRSA-induced cSSTIs, and the combination of vancomycin and rifampicin may be the most effective treatment for MRSA-induced pneumonia. More high-quality studies are still needed in the future to further identify alternatives to vancomycin. Trial registration: PROSPERO registration number CRD42023416788.<\/jats:p>","DOI":"10.3390\/antibiotics13090866","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T10:20:10Z","timestamp":1725963610000},"page":"866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"He","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewei","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahan","family":"Yang","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhi","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Dong","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0869-8867","authenticated-orcid":false,"given":"Ying","family":"Luo","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9836-0252","authenticated-orcid":false,"given":"Yuzhu","family":"Song","sequence":"additional","affiliation":[{"name":"College of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China"},{"name":"Graduate School, Kunming University of Science and Technology, Kunming 650500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jcp.14.4.385","article-title":"Methicillin-resistant staphylococci","volume":"14","author":"Barber","year":"1961","journal-title":"J. Clin. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3201\/eid0702.010204","article-title":"The changing epidemiology of Staphylococcus aureus?","volume":"7","author":"Chambers","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","article-title":"Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"357","author":"Daum","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/sur.2005.6.283","article-title":"Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance","volume":"6","author":"Lee","year":"2005","journal-title":"Surg. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","unstructured":"Healthcare Cost Utilization Project (2009). HCUP Facts and Figures. HCUP Facts and Figures: Statistics on Hospital-Based Care in the United States, 2007, Agency for Healthcare Research and Quality."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chalmers, S.J., and Wylam, M.E. (2020). Methicillin-Resistant Staphylococcus aureus Infection and Treatment Options, Humana. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-9849-4_16"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Samura, M., Kitahiro, Y., Tashiro, S., Moriyama, H., Hamamura, Y., Takahata, I., Kawabe, R., Enoki, Y., Taguchi, K., and Takesue, Y. (2022). Efficacy and Safety of Daptomycin versus Vancomycin for Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus with Vancomycin Minimum Inhibitory Concentration > 1 \u00b5g\/mL: A Systematic Review and Meta-Analysis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040714"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1248\/bpb.b22-00276","article-title":"Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM","volume":"45","author":"Matsumoto","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12450","article-title":"European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid","volume":"20","author":"Chastre","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/21.suppl_A.81","article-title":"Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: Preliminary results","volume":"21","author":"Hermans","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2165\/00044011-199612020-00003","article-title":"Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia","volume":"12","author":"Liu","year":"1996","journal-title":"Clin. Drug Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/01.inf.0000087020.75886.93","article-title":"Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","article-title":"Linezolid eradicates MRSA better than vancomycin from surgical-site infections","volume":"188","author":"Weigelt","year":"2004","journal-title":"Am. J. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria","volume":"40","author":"Stryjewski","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","article-title":"A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria","volume":"62","author":"Katz","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dkn250","article-title":"Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A Phase 3, multicentre, double-blind, randomized study","volume":"62","author":"Florescu","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am. J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CCM.0b013e3181b9ecea","article-title":"Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia","volume":"38","author":"Jung","year":"2010","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.ijid.2010.10.003","article-title":"The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: Results from three randomized controlled trials","volume":"15","author":"Lipsky","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: The second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2217\/fmb.10.138","article-title":"ATLAS trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections","volume":"5","author":"Barriere","year":"2010","journal-title":"Future Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/sur.2011.062","article-title":"Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease","volume":"13","author":"Duane","year":"2012","journal-title":"Surg. Infect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.clinthera.2012.06.018","article-title":"Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: A retrospective, propensity score-matched, case-control analysis","volume":"34","author":"Itani","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jac\/dks081","article-title":"Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections","volume":"67","author":"Stryjewski","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: The ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jemermed.2015.07.026","article-title":"Randomized controlled noninferiority trial comparing daptomycin to vancomycin for the treatment of complicated skin and skin structure infections in an observation unit","volume":"49","author":"Shaw","year":"2015","journal-title":"J. Emerg. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12879-016-1779-5","article-title":"The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: Data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin","volume":"16","author":"Equils","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref_49","first-page":"47","article-title":"A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase III Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection","volume":"66","author":"Dube","year":"2018","journal-title":"J. Assoc. Physicians India"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014Results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101790","DOI":"10.1016\/j.eclinm.2022.101790","article-title":"Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial","volume":"56","author":"Kotsaki","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijantimicag.2012.08.004","article-title":"A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection","volume":"40","author":"Bally","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40121-021-00456-0","article-title":"Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis","volume":"10","author":"Feng","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107109","DOI":"10.1016\/j.ijid.2024.107109","article-title":"Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis","volume":"146","author":"Ju","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jama.2011.174","article-title":"IDSA creates MRSA treatment guideline","volume":"305","author":"Kuehn","year":"2011","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1185\/03007990903454912","article-title":"Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis","volume":"26","author":"Bounthavong","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/phar.1458","article-title":"Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.clinthera.2016.06.014","article-title":"Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous\/Oral Sequential Administrations in Healthy Chinese Subjects","volume":"38","author":"Chen","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.32.9.1320","article-title":"Vancomycin concentrations in infected and noninfected human bone","volume":"32","author":"Graziani","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0732-8893(02)00543-6","article-title":"Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)","volume":"45","author":"Rennie","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1469-0691.12463","article-title":"European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid","volume":"20","author":"Bassetti","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:53:15Z","timestamp":1760111595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["antibiotics13090866"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13090866","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}